Compare MAMA & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAMA | BMEA |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 598.8M | 138.1M |
| IPO Year | 2011 | 2021 |
| Metric | MAMA | BMEA |
|---|---|---|
| Price | $13.93 | $1.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $19.00 | $9.83 |
| AVG Volume (30 Days) | 329.8K | ★ 1.2M |
| Earning Date | 04-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 44.44 | ★ 69.19 |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $95,420,129.00 | N/A |
| Revenue This Year | $31.09 | N/A |
| Revenue Next Year | $16.12 | N/A |
| P/E Ratio | $111.54 | ★ N/A |
| Revenue Growth | ★ 95.54 | N/A |
| 52 Week Low | $7.61 | $0.87 |
| 52 Week High | $17.85 | $3.07 |
| Indicator | MAMA | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 43.05 | 44.62 |
| Support Level | $12.86 | $1.23 |
| Resistance Level | $14.88 | $1.45 |
| Average True Range (ATR) | 0.65 | 0.11 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 29.39 | 36.08 |
Mama's Creations Inc manufactures and markets fresh deli-prepared foods distributed through grocery, mass, club, and convenience stores across the United States. Its product portfolio includes refrigerated prepared foods such as meatballs, meatloaf, sausage products, and pasta and rice entrees. The products are principally sold to supermarkets, club chains, mass-market retailers, and food distributors. The brand of the company includes Mama's Creations, Mama's Mancini's, The Olive Branch, Creative Salads, and others.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.